[Prophylaxis and treatment of cytomegalovirus infection in allogeneic bone marrow transplantation].
To assess the efficacy and safety of Cymevene (ganciclovir) in the prophylaxis and treatment of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation (allo-BMT). Sixty patients with leukemia undergoing allo-BMT were observed. Cymevene was given prophylactically to 20 patients at a dose of 5 mg/kg twice daily from day -9 to day -2 and restarted when the ANC > or = 1.0 x 10(9)/L and BPC > or = 30 x 10(9)/L at a daily dose of 5 mg/kg for 5 days every week until day +100. In diagnosed symptomatic CMV infections, the dose of Cymevene was 5 mg/kg twice daily for 2-3 weeks followed by 5 mg/kg twice a day for 5 days every week for an additional 2-3 weeks. The incidence of active CMV infection was 0 in the prophylaxis-treated patients and 25% in the controls (P < 0.05). In diagnosed CMV diseases, marked improvement was noted in 17 of 20 patients (85%) treated with Cymevene. The most common adverse events of Cymevene were leukopenia and thrombocytopenia, but were reversible. Cymevene is effective and safe for the prophylaxis and treatment of CMV infections after allo-BMT.